Posts Categorized: Uncategorized

ACTO Acquires CoHealth!

ACTO, the Omnichannel Education and Engagement  platform for life sciences, today announced its acquisition of UTEST company, CoHealth, a mobile application that provides trusted resources for patients and caregivers. The deal is ACTO’s second strategic acquisition since securing $11.5 million this summer, and brings a new division with direct-to-patient education capabilities to ACTO’s SaaS platform. Founded in… Read more »

LegUp Computing Acquired by Microchip!

Microchip Technology Inc. (Nasdaq: MCHP) today announced it acquired UTEST company, LegUp Computing Inc., expanding its Field-Programmable Gate Array (FPGA)-based edge compute solution stack with a high-level synthesis (HLS) tool. Commercialized from University of Toronto research, the LegUp HLS tool will make it easier for a larger community of software engineers to harness the algorithm-accelerating power of… Read more »

PHENOMIC AI RAISES $7.97 MILLION CAD TO IDENTIFY PROMISING CANCER DRUGS

UTEST 2017 company, Phenomic AI, which aims to help researchers spot the differences between cells that could be early signs of disease and identify promising drugs, has raised $7.97 million CAD ($6 million USD) in financingThis latest round, which the Phenomic AI classified as seed financing, brings the company’s total raised to date to approximately… Read more »

UTEST 2020 COHORT APPLICATIONS OPEN!

UTEST is announcing its ninth call for UofT companies. UTEST provides UofT start-up companies with seed funding of up to $150,000 in the form of a SAFE, 12 months of incubation space*, intense entrepreneurial education provided by MaRS, corporate and intellectual property legal support, mentoring and business strategy support. Our program partner, TIAP, provides sector expertise, an Entrepreneurs-in-Residence (EIR) program and follow-on… Read more »

DEEP GENOMICS RAISES $40M SERIES B

UTEST 2015 cohort startup, Deep Genomics, has closed a $40 million Series B. This brings the company’s total funding to-date to $61 million. The round was led by Future Ventures and received investments from Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures. The financing will be put toward the development of treatments for rare genetic… Read more »

EBT Secures USD$10M Series A

EBT Medical, Inc., a 2018 UTEST company, is developing disruptive neuromodulation therapies for pelvic health disorders, recently secured a USD$10M Series A investment, co-led by two top-tier venture capital firms, SV Health Investors and Genesys Capital. EBT intends to use the funding to further develop its revolutionary noninvasive neuromodulation technology, as well as to pursue… Read more »

ODAIA RAISES $1.6 MILLION TO COMMERCIALIZE ITS PREDICTIVE AI PLATFORM

UTEST 2018 company, ODAIA an AI-powered software-as-a-service (SaaS) startup has raised $1.6 million in seed funding to help fuel its predictive customer analytics tool. The round as co-led by StandUp Ventures and Panache Ventures, which earlier today announced the final close of its Fund I. ODAIA’s seed round also saw participation from BDC Capital’s Women in Technology… Read more »

DEEP GENOMICS DISCOVERS GENETIC DISORDER TREATMENT DRUG VIA AI

Deep Genomics, UTEST cohort 2015, a Toronto-based AI therapeutics startup, has made the first-ever discovery of a diseases treatment and drug candidate using artificial intelligence. The startup announced on Wednesday that its propriety AI-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare and potentially life-threatening… Read more »

GENE42 LAUNCH CANADA’S FIRST NATIONAL RARE DISEASE RESEARCH PLATFORM

Gene42, a UTEST company from the 2015 cohort, recently launched Genomics4RD, Canada’s first national rare disease research platform, in partnership with research association Care4Rare. Care4Rare and Gene42 built Genomics4RD as part of a national initiative funded by Genome Canada. The project is focused on employing multi-omics, an approach to biological analysis, to deliver diagnostic care for rare genetic… Read more »

AmacaThera raises $3.25M

AmacaThera a UTEST company from 2015, has raised $3.25 million to develop a gel-based drug delivery system that could eliminate the need to give patients powerful painkillers following surgery – a key source of the current opioid crisis. The startup, AmacaThera, is built on a gel technology developed in the U of T lab of Molly Shoichet, Ontario’s… Read more »